Thus, the drug stimulates Beclin1, Atg5, and Atg12 expression in HCC cells in vitro (Yuan et al., 2014), Beclin-1 expression is increased by sorafenib in a time-dependent fashion in Hep3B cells (Carr et al., 2013), sorafenib can mildly induce Beclin1 and Atg-5 expression whereas decreases p62 expression in a significant manner in PLC-5 cells (Tai et al., 2013), or increases Atg5, Vps34 and Beclin-1, decreases p62 and does not affect UVRAG expression in Huh7 and HepG2 cells (Zhai et al., 2014). The gene discussed is ATG5; the disease is hepatocellular carcinoma.